



The TIMI Trials

TIMI 15A

OBJECTIVE: To evaluate the pharmacodynamic response, safety and pharmacokinetics of various doses of the GP IIb/IIIa inhibitor RPR 109891 given intravenously for the treatment of patients with acute coronary syndromes.

TIMI 15B

OBJECTIVE: To evaluate the pharmacodynamic response, safety and pharmacokinetics of the GP IIb/IIIa inhibitor RPR 109891 given intravenously followed by oral administration for the treatment of patients with acute coronary syndromes.

1. Giugliano RP, McCabe CH, Sequeria RF, Frey MJ, Henry TD, Piana RN, Tamby JF, Jensen BK, Nicolas SB, Jennings LK, Wise RJ, Braunwald E for the TIMI 15A and 15B Investigators. First report of an intravenous and oral GP IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15a and 15b trials. *Am Heart J* 2000; 140: 81-93.